Authors: Mross, K Berdel, WE Fiebig, HH Velagapudi, R von Broen, IM Unger, C

Citation: K. Mross et al., Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer, ANN ONCOL, 9(12), 1998, pp. 1323-1330